BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock

Key Points

• BTIG Research has increased its target price for Monopar Therapeutics (NASDAQ:MNPR) from $87.00 to $104.00, suggesting a potential upside of 42.39% from the previous close.
• Several analysts have issued ratings on Monopar Therapeutics, with one Strong Buy, eight Buy, and one Hold, leading to a consensus average target price of $80.22.
• Monopar Therapeutics reported a loss of ($0.35) EPS in its last quarterly results, outperforming the consensus estimate of ($0.47).

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) had its target price lifted by BTIG Research from $87.00 to $104.00 in a report released on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's price objective would suggest a potential upside of 42.39% from the stock's previous close.

Other analysts have also issued research reports about the stock. Oppenheimer began coverage on shares of Monopar Therapeutics in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $77.00 price target on the stock. HC Wainwright began coverage on shares of Monopar Therapeutics in a research report on Tuesday, August 26th. They set a "buy" rating and a $70.00 price target on the stock. Raymond James Financial began coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 2nd. They set a "strong-buy" rating and a $80.00 price target on the stock. Lake Street Capital started coverage on shares of Monopar Therapeutics in a research report on Tuesday. They set a "buy" rating and a $106.00 price target on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $74.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Monopar Therapeutics has a consensus rating of "Buy" and an average target price of $80.22.

Monopar Therapeutics Price Performance

MNPR opened at $73.04 on Thursday. The company's 50 day simple moving average is $43.25 and its two-hundred day simple moving average is $38.70. Monopar Therapeutics has a 1-year low of $4.12 and a 1-year high of $74.00. The firm has a market capitalization of $450.66 million, a price-to-earnings ratio of -21.93 and a beta of 1.20.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.12. On average, equities analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the director owned 5,173 shares in the company, valued at $206,920. The trade was a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Chandler Robinson sold 16,800 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,504 shares of company stock valued at $1,700,160 over the last quarter. 20.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors have recently modified their holdings of MNPR. Affinity Asset Advisors LLC acquired a new position in shares of Monopar Therapeutics in the first quarter worth $2,257,000. Geode Capital Management LLC grew its stake in shares of Monopar Therapeutics by 99.7% in the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after acquiring an additional 48,379 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Monopar Therapeutics in the first quarter worth $673,000. Jane Street Group LLC acquired a new position in shares of Monopar Therapeutics in the first quarter worth $377,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Monopar Therapeutics during the first quarter worth $328,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.